October 19, 2016

Study Shows That Therapeutic Drug Monitoring Can Reduce Paclitaxel-Associated Neuropathy

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced…
Read More
June 9, 2015

Saladax Biomedical, Inc. Announces Presentation of CEPAC-TDM Study of Paclitaxel in Non-Small Cell Lung Cancer at 2015 ASCO Meeting

Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Saladax Biomedical, Inc.…
Read More
June 8, 2015

Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting

Advantages of a Practical Approach to Personalized Dosing of 5-FU Demonstrated Saladax Biomedical, Inc. recently…
Read More
December 1, 2014

Saladax Biomedical Announces U.S. Launch of MyImatinib™ Chemotherapy Exposure Optimization Test

Commercial Launch of MyImatinib™ Test Expands MyCare™ portfolio of Chemotherapy Exposure Optimization tests available from…
Read More
July 23, 2014

Personalized Chemotherapy Tests Cleared for Use in China

Exposure Optimization Tests Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today…
Read More